Actively Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
Led by Verismo Therapeutics · Updated on 2026-04-14
36
Participants Needed
5
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
CONDITIONS
Official Title
SynKIR-310 for Relapsed/Refractory B-NHL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult 18 years of age and older
- Histologically confirmed diagnosis of B-cell non-Hodgkin lymphoma
- Have received prior CAR T therapy or are unwilling/unable to receive prior CAR T
- Have refractory or relapsed disease after 2 prior lines of therapy
- If relapsed/refractory after autologous stem cell transplant, transplant must be at least 6 months prior
- If relapsed/refractory after allogeneic stem cell transplant, transplant must be at least 6 months prior without graft versus host disease and expected to remain off immunosuppressive therapy during the trial
- Measurable disease at enrollment per defined criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
You will not qualify if you...
- Treatment with any investigational agent within 30 days prior to screening
- Previous or concurrent malignancy except adequately treated non-melanoma skin cancer, carcinoma in-situ treated over 3 years ago, melanoma skin cancer in-situ, or other malignancy in complete remission for 5 years, or treated prostate cancer with PSA < 1.0
- Use of systemic immunosuppressive drugs within 4 weeks prior to study or anticipated use through study end, except non-T cell targeting agents prior to leukapheresis
- Known immunodeficiency disease except hypoglobulinemia
- Active or relevant primary central nervous system disorder unless recovered/remission without recurrence for 2 years
- Uncontrolled hypertension, history of myocarditis, congestive heart failure, unstable angina, serious cardiac arrhythmia, or recent myocardial infarction within 6 months
- Any active uncontrolled systemic fungal, bacterial, or viral infection
- Other protocol-defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
2
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
3
The University of Kansas Cancer Center
Fairway, Kansas, United States, 66205
Actively Recruiting
4
Rutgers Cancer Institute
New Brunswick, New Jersey, United States, 08902
Actively Recruiting
5
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
P
Physician Connect
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here